Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Vertex gains FDA fast track designation for diabetes stem cell therapy

Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients

- PMLiVE

GSK, Vir seek EUA after scoring positive results for COVID-19 antibody VIR-7831

VIR-7831 reduced the risk of hospitalisation/death by 85% in high-risk COVID-19 patients

- PMLiVE

Ashfield Engage taps Keith Buckby as UK business development director

Buckby returns to Ashfield Engage after having previously worked for Ashfield for over 11 years

- PMLiVE

EMA starts rolling review of Lilly’s COVID-19 antibodies

CHMP will review the combination of bamlanivimab and etesemivab as well as bamlanivimab monotherapy

- PMLiVE

Helping patients to help themselves – how pharma can get more from patient support programmes

By Chris Finch

- PMLiVE

Synergy Vision becomes an employee-owned company

Majority shareholding will be held collectively in an employee ownership trust

- PMLiVE

Researchers use AI to identify drugs that could be repurposed for Alzheimer’s

Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing

- PMLiVE

bluebird bio says AML case “very unlikely” to be related to gene therapy LentiGlobin

bluebird bio's gene therapy LentiGlobin is used to treat sickle cell disease

LUCID GROUP PARTNERS WITH NEW INVESTOR ICG

Lucid Group has secured a new investment from Intermediate Capital Group (ICG) to support its continued ambition to build a global business that delivers life transforming value for everyone.Founded in...

Lucid Group Communications Limited

- PMLiVE

Stakeholder meeting kick-starts dialogue on COVID-19 vaccine supply chain issues

Meeting discussed potential solutions to COVID-19 vaccine manufacturing bottlenecks

- PMLiVE

Pfizer/BioNTech could supply three billion doses of COVID-19 vaccine in 2022

J&J reportedly facing vaccine supply issues in the EU

- PMLiVE

Novartis’ canakinumab misses the mark in previously treated NSCLC

Drug failed to improve survival in previously-treated metastatic NSCLC patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links